Purple Biotech logo

Purple BiotechNASDAQ: PPBT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

20 November 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$5.03 M
-93%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 30 Oct 2024 22:43:37 GMT
$3.21-$0.22(-6.41%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PPBT Latest News

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
globenewswire.com18 September 2024 Sentiment: POSITIVE

REHOVOT, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today reported new positive biomarker findings for its lead oncology therapeutic candidate CM24. These data were presented yesterday at the American Association for Cancer Research® (AACR) Special Conference on Advances in Pancreatic Cancer Research currently ongoing in Boston, in a poster titled, “Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer”.

What Makes Purple Biotech (PPBT) a New Buy Stock
zacks.com21 August 2024 Sentiment: POSITIVE

Purple Biotech (PPBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
globenewswire.com16 August 2024 Sentiment: POSITIVE

Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology ( ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination of CM24+nivolumab and NAL-IRI/5FU/LV chemotherapy cohort

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
globenewswire.com01 July 2024 Sentiment: POSITIVE

REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3 (File Nos. 333-268710, 333-235327 and 333-215037). The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions.

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
globenewswire.com27 June 2024 Sentiment: POSITIVE

REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today reported additional positive interim data from its randomized, controlled, open label, multicenter Phase 2 study (NCT 04731467) of CM24, in combination with Bristol Myers Squibb's immune checkpoint inhibitor nivolumab and standard of care (SoC) chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (PDAC). These results suggest that serum MPO may be a predictive biomarker for survival in the CM24+Nivolumab + Nal-IRI/5FU/LV arm. The company also announced that it will host a virtual KOL event on Thursday, July 11, 2024 at 10:30 AM ET to discuss the results in detail. To register for the event, click here.

Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher
Zacks Investment Research13 March 2024 Sentiment: POSITIVE

Purple Biotech Ltd. Sponsored ADR (PPBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.

PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
InvestorPlace05 March 2024 Sentiment: NEGATIVE

Purple Biotech (NASDAQ: PPBT ) just reported results for the fourth quarter of 2023. Purple Biotech reported earnings per share of -19 cents.

What type of business is Purple Biotech?

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

What sector is Purple Biotech in?

Purple Biotech is in the Healthcare sector

What industry is Purple Biotech in?

Purple Biotech is in the Biotechnology industry

What country is Purple Biotech from?

Purple Biotech is headquartered in Israel

When did Purple Biotech go public?

Purple Biotech initial public offering (IPO) was on 20 November 2015

What is Purple Biotech website?

https://purple-biotech.com

Is Purple Biotech in the S&P 500?

No, Purple Biotech is not included in the S&P 500 index

Is Purple Biotech in the NASDAQ 100?

No, Purple Biotech is not included in the NASDAQ 100 index

Is Purple Biotech in the Dow Jones?

No, Purple Biotech is not included in the Dow Jones index

When was Purple Biotech the previous earnings report?

No data

When does Purple Biotech earnings report?

Next earnings report date is not announced yet